Conclusions: Podoplanin is a strong and independent prognostic factor for staging and survival in the group of patients with p16 negative but not with p16 positive OPSCC and may be considered as a cofactor in risk stratification and therapeutic decisions in patients with prognostically unfavourable p16 negative OPSCC. PO-102 Reirradiation and cetuximab in patients with recurrent, unresectable previously irradiated head and neck cancer D. Milanovic 1 , A.L. Grosu 1 , M. Henke 1 1 Universitätsklinik Freiburg, Department of Radiation Oncology, Freiburg, Germany Purpose/Objective: The treatment of patients with loco- regionally recurrent, unresectable and previously irradiated head and neck cancer (HNSCC) is a continuing challenge. Due to the fact that the predominant cause of death of these patients is uncontrolled local progression, it has been supposed that reirradiation (re-RT) may play important role achieving local control, but median survival achieved with this therapeutic modality is approximately 10 months. The overexpression of epidermal growth factor receptor (EGFR ), which is not only responsible for progression but also for increased resistance toward RT, is one of the most important molecular biological characteristics of HNSCC. We propose that better response to re-RT will be reached in case of simultaneous EGFR inhibition with cetuximab. The purpose of this retrospective study was to investigate the feasibili-ty, toxicity, and outcome of re-RT combined with cetuximab in pa-tients with inoperable, previously irradiated recurrent HNSCC. Materials and Methods: Between June 2008 and August 2014, 34 patients with inoperable and previously irradiated HNSCC were reirradiated Concomitant EGFR blockade (cetuximab) was given initially at 400 mg/m 2 two days prior to re-RT and weekly (250 mg/m 2 ) thereafter. Results: 31 patients completed Re-RT (50.4-66.6 Gy, 5 X 1.8 Gy/Week) and received cetuximab as prescribed. One patient died of anaphylactic shock, two discontinued study- participation on their own request. Grade 3 side effects were documented for dermatitis (25.8%,) dysphagia (12.9%), acneiform rash (22.5%), mucositis (9.6%), voice change (9.6 %) and pain (9.6%). Median overall and progression-free survival times were 10.4 and 5.2 months, respectively. Conclusions: To the best of our knowledge, we report here the largest study where safety and efficacy of re-RT and concur-rent EGFR blockade have been investi-gated. We documented significant longer median overall surviv-al if patients developed acneiform rash grade 2–3 compared to patients with-out this cetuximab-related complication (14 months vs. 6 months) and sig-nificant shorter survival times in patients who relapsed more than 120 months after finishing primary RT course. Taken together, compared to standard combined therapy (cisplatin,5-Fluorouracil and cetuximab) this therapeutic strategy did not demonstrate survival benefit. PO-103 Comparison of VEGF Expression in non malignant, premalignant lesion and squamous cell carcinoma of oral cavity M. Gupta 1 , N. Husain 2 , R. Mehrotra 3 1 Christian Medical College Hospital, General Pathology, Vellore, India 2 RML Medical College & Hospital, Pathology, Lucknow, India 3 King George Medical University, Pathology, Lucknow, India Purpose/Objective: To compare vascular endothelial growth factor (VEGF) expression in non malignant lesion (stratified squamous epithelium overlying pyogenic granuloma), premalignant lesion (leukoplakia) and squamous cell carcinoma (SCC) of oral cavity and further to evaluate expression in relation to grade of the tumour. Materials and Methods: Immunohistochemical expression of VEGF in 90 cases of oral SCC [30 cases each of well differentiated (WD), moderately differentiated (MD) and poorly differentiated (PD) carcinoma] and 30 cases each of leukoplakia and pyogenic granuloma were evaluated. VEGF expression observed as brown intracytoplasmic staining, was counted in 500 squamous cells in all cases. On the basis of intensity and percentage positivity VEGF score and VEGF grade were calculated. The intensity of VEGF staining in individual cells was graded as negative, +, ++, +++. Number of squamous cells showing VEGF expression of varying intensity was counted and VEGF score was calculated as below Number of cells with negative VEGF expression × 0 = A Number of cells with 1(+) intensity × 1 = B Number of cells with 2(++) intensity × 2 = C Number of cells with 3(+++) intensity × 3 = D VEGF score = A+B+C+D VEGF score for individual cases was calculated and mean score was obtained for each of the 5 groups VEGF grading on the basis of the score obtained for each tumor was done in the following way: VEGF grade VEGF score Grade-0 0-50 Grade-1 51 - 500 Grade 2 501-1000 Grade 3: 1001 – 1500 5TH ICHNO page 51